# Nuclide record neuro-imaging-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/roadmaps/neuro-imaging-roadmap/>
  a schema:CreativeWork ;
  nuclide:kind "roadmap" ;
  schema:identifier "neuro-imaging-roadmap" ;
  schema:name "Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma"@en ;
  schema:description "Ordinary sugar-based PET scans do not work well in the brain because healthy brain tissue itself uses a lot of sugar. Nuclear medicine had to develop tracers that light up brain tumours specifically, first amino acid tracers for gliomas and then a receptor tracer that also opens the door to a matched radioactive treatment for meningioma."@en ;
  schema:url <https://nuclide.cc/roadmaps/neuro-imaging-roadmap/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/25635133/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6351513/>, <https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00193-7/fulltext>, <https://clinicaltrials.gov/study/NCT07150806> ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/c-11/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/glioblastoma/>, <https://nuclide.cc/indications/meningioma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/pet/>, <https://nuclide.cc/technologies/pet-ct/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/astatine-211-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fludeoxyglucose-f18/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/ryz101/> .